Quantcast

Latest Ipilimumab Stories

2012-06-06 05:34:10

(Ivanhoe Newswire) — Clinical trials have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer. Johns Hopkins Kimmel Cancer Center is leading a clinical study testing experimental drugs aimed at restoring the immune system´s ability to spot and attack cancer. “Based on the positive response rates to these drugs and longevity of many of these responses, we believe that new clinical trials should move...

2012-03-15 23:37:11

Antibodies, once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way, say cancer researchers at the Georgetown Lombardi Comprehensive Cancer Center In a review article posted online March 16 in Cell, the researchers say that refinements and modifications of monoclonal antibody drugs -- several of which have already revolutionized the care of breast and colon cancer --are now being tested in most tumor types. These modifications...

2012-03-08 13:43:48

Study describes a rare case of the abscopal effect in a melanoma patient Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer. The size of both the...

117736034
2011-08-22 13:01:29

The first new skin cancer treatment since the 1970s has now gone on sale in Britain, according to a Monday morning article by Telegraph Health Correspondent Martin Beckford. The drug is known as ipilimumab, and according to the American Cancer Society, it is "a type of immunotherapy known as a monoclonal antibody," which is definite as "a man-made version of an immune system protein that fits like a lock and key with a certain protein in the body." "Ipilimumab is designed to seek out...

1bba6e6ced73cce47ad966bbae6ea6d3
2011-08-18 10:55:00

The US Food and Drug Administration (FDA) on Wednesday approved the cancer treatment drug Zelboraf, used to treat patients with late-stage or unresectable melanoma, the most dangerous form of skin cancer. The drug specifically treats patients with melanoma whose tumors express a gene mutation called BRAF V600E. The drug has not been tested on patients whose melanoma tests negative for the mutation by an approved FDA diagnostic. Zelboraf is being approved with a test called the cobas 4800...

2011-06-06 12:56:15

A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators. The findings (abstract 8511), will be presented in an oral session at the annual meeting of the American Society of Clinical Oncology on Saturday, June 4, 3 p.m. CT, Arie Crown Theater, McCormick Place. The drugs --...

c7d7d7588c7904c027290ba4e1c2ec19
2011-06-06 12:35:00

A new study found that people with advanced melanoma who were treated with Bristol-Myers Squibb Co.'s Yervoy plus chemotherapy lived an average of two months longer than people who got chemotherapy alone. The study is the first to show that combining chemotherapy and an immune-system treatment is safe and effective for patients with advanced melanoma. It is also the second major trial to show Yervoy (ipilimumab), a new type of immunotherapy drug, can improve survival in patients with the...

2011-04-28 00:15:44

Like brainy bookworms unprepared for the rough and tumble of post-graduation life, white blood cells trained by scientists to attack tumors tend to fade away quickly when injected into cancer patients. Dana-Farber Cancer Institute scientists, however, have developed a technique that can cause such cells to survive in patients' bloodstreams for well over a year, in some cases, without the need of other, highly toxic treatments, a new study shows. In a paper published in the Apr. 27 issue of...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related